Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: ViroPharma Inc.
So what: The FDA declined industrial-scale manufacturing of Cinryze, which treats a fatal genetic disorder called hereditary angioedema. Regulators are looking for more information after observations at pre-approval inspections and a review of the process.
Now what: The company still plans to move forward with higher production assuming risk moving forward. After pummeling the stock 17% in pre-market trading, the stock is up significantly on the day. The risks seem minimal going forward, so barring further setbacks I view this dip as a short-term buying opportunity.
Interested in more info on ViroPharma? Add it to your watchlist here by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.